+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Advanced Recurrent Ovarian Cancer Market by Disease Type, Treatment Type - Global Forecast 2025-2030- Product Image
Advanced Recurrent Ovarian Cancer Market by Disease Type, Treatment Type - Global Forecast 2025-2030- Product Image
Sale

Advanced Recurrent Ovarian Cancer Market by Disease Type, Treatment Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015026
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Advanced Recurrent Ovarian Cancer Market grew from USD 1.43 billion in 2023 to USD 1.53 billion in 2024. It is expected to continue growing at a CAGR of 9.15%, reaching USD 2.64 billion by 2030.

Advanced Recurrent Ovarian Cancer (AROC) affects patients who have experienced a return of cancer post-treatment and is characterized by its aggression and limited responsiveness to standard therapies. The necessity for advanced research and treatment in AROC is critical as it remains one of the deadliest gynecological cancers due to late-stage diagnosis and recurrence. The application scope revolves around enhancing therapeutic approaches, drug efficacy, and patient quality of life, targeting healthcare providers, pharmaceutical companies, and research institutions as end-users. Market insights reveal key growth influencers: the rising prevalence of ovarian cancer, increased awareness, and technological advances in oncology drug development. Latest opportunities lie in personalized medicine, improved diagnostic tools, and targeted therapies like PARP inhibitors. Companies can leverage these by enhancing drug pipelines, collaborating on research projects, and engaging in strategic partnerships to develop tailored solutions. However, market growth is challenged by factors such as high treatment costs, limited patient access to cutting-edge therapies in developing regions, regulatory hurdles, and the intrinsic complexity of ovarian cancer biology that complicates drug development. Despite these limitations, the potential for innovation exists in biomarker discovery to facilitate early diagnosis and specialized treatment plans, as well as in exploring combinatorial treatment regimens incorporating immunotherapies alongside existing drugs to improve patient outcomes. Therefore, businesses should focus on expanding R&D investment, adopting data-driven approaches to tailor treatment strategies, and fostering cross-sector collaboration to drive innovation. By embracing patient-centered care solutions and technology-backed diagnostics, enterprises can significantly influence the market's trajectory. The nature of the AROC market is dynamic and research-intensive, requiring continual adaptation to new scientific findings and treatment paradigms that promise to enhance survival rates and patient experiences.

Understanding Market Dynamics in the Advanced Recurrent Ovarian Cancer Market

The Advanced Recurrent Ovarian Cancer Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing development and approval of targeted therapies specifically for recurrent ovarian cancer
    • Expanding clinical trial programs focused on innovative treatments for advanced recurrent ovarian cancer
    • Collaborations between pharmaceutical companies and research institutions advancing novel treatment approaches
    • Increasing investment in personalized medicine boosting effective treatment strategies for recurrent ovarian cancer
  • Market Restraints
    • Lack of early diagnosis and specific biomarkers for advanced recurrent ovarian cancer
    • Adverse side effects and toxicity associated with current treatment protocols for advanced recurrent ovarian cancer
  • Market Opportunities
    • Application of artificial intelligence and machine learning in predicting treatment responses and outcomes for advanced recurrent ovarian cancer
    • Development of educational programs and resources for healthcare professionals specializing in advanced recurrent ovarian cancer
    • Integration of patient-reported outcomes and real-world evidence into clinical trials for more personalized therapy in advanced recurrent ovarian cancer
  • Market Challenges
    • Ensuring adequate funding and resources for advanced recurrent ovarian cancer research
    • Addressing patient accessibility and affordability of advanced recurrent ovarian cancer therapies.

Exploring Porter’s Five Forces for the Advanced Recurrent Ovarian Cancer Market

Porter’s Five Forces framework further strengthens the insights of the Advanced Recurrent Ovarian Cancer Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Advanced Recurrent Ovarian Cancer Market

External macro-environmental factors deeply influence the performance of the Advanced Recurrent Ovarian Cancer Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Advanced Recurrent Ovarian Cancer Market

The Advanced Recurrent Ovarian Cancer Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Advanced Recurrent Ovarian Cancer Market

The Advanced Recurrent Ovarian Cancer Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Advanced Recurrent Ovarian Cancer Market

The Advanced Recurrent Ovarian Cancer Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Advanced Recurrent Ovarian Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Genentech, GSK, ImmunoGen, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Seagen, Tesaro, and Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Advanced Recurrent Ovarian Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
    • Epithelial Ovarian Cancer
      • Clear Cell
      • Endometrioid
      • Mucinous
      • Serous
    • Non-Epithelial Ovarian Cancer
      • Germ Cell Tumors
      • Stromal Tumors
  • Treatment Type
    • Chemotherapy
      • Non-Platinum Chemotherapy
        • Docetaxel
        • Paclitaxel
      • Platinum-Based Chemotherapy
        • Carboplatin
        • Cisplatin
    • Hormonal Therapy
      • Letrozole
      • Tamoxifen
    • Targeted Therapy
      • Anti-Angiogenic Agents
        • Bevacizumab
      • PARP Inhibitors
        • Niraparib
        • Olaparib
        • Rucaparib
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing development and approval of targeted therapies specifically for recurrent ovarian cancer
5.1.1.2. Expanding clinical trial programs focused on innovative treatments for advanced recurrent ovarian cancer
5.1.1.3. Collaborations between pharmaceutical companies and research institutions advancing novel treatment approaches
5.1.1.4. Increasing investment in personalized medicine boosting effective treatment strategies for recurrent ovarian cancer
5.1.2. Restraints
5.1.2.1. Lack of early diagnosis and specific biomarkers for advanced recurrent ovarian cancer
5.1.2.2. Adverse side effects and toxicity associated with current treatment protocols for advanced recurrent ovarian cancer
5.1.3. Opportunities
5.1.3.1. Application of artificial intelligence and machine learning in predicting treatment responses and outcomes for advanced recurrent ovarian cancer
5.1.3.2. Development of educational programs and resources for healthcare professionals specializing in advanced recurrent ovarian cancer
5.1.3.3. Integration of patient-reported outcomes and real-world evidence into clinical trials for more personalized therapy in advanced recurrent ovarian cancer
5.1.4. Challenges
5.1.4.1. Ensuring adequate funding and resources for advanced recurrent ovarian cancer research
5.1.4.2. Addressing patient accessibility and affordability of advanced recurrent ovarian cancer therapies.
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Advanced Recurrent Ovarian Cancer Market, by Disease Type
6.1. Introduction
6.2. Epithelial Ovarian Cancer
6.2.1. Clear Cell
6.2.2. Endometrioid
6.2.3. Mucinous
6.2.4. Serous
6.3. Non-Epithelial Ovarian Cancer
6.3.1. Germ Cell Tumors
6.3.2. Stromal Tumors
7. Advanced Recurrent Ovarian Cancer Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.2.1. Non-Platinum Chemotherapy
7.2.1.1. Docetaxel
7.2.1.2. Paclitaxel
7.2.2. Platinum-Based Chemotherapy
7.2.2.1. Carboplatin
7.2.2.2. Cisplatin
7.3. Hormonal Therapy
7.3.1. Letrozole
7.3.2. Tamoxifen
7.4. Targeted Therapy
7.4.1. Anti-Angiogenic Agents
7.4.1.1. Bevacizumab
7.4.2. PARP Inhibitors
7.4.2.1. Niraparib
7.4.2.2. Olaparib
7.4.2.3. Rucaparib
8. Americas Advanced Recurrent Ovarian Cancer Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Advanced Recurrent Ovarian Cancer Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Advanced Recurrent Ovarian Cancer Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ADVANCED RECURRENT OVARIAN CANCER MARKET RESEARCH PROCESS
FIGURE 2. ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ADVANCED RECURRENT OVARIAN CANCER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. ADVANCED RECURRENT OVARIAN CANCER MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ADVANCED RECURRENT OVARIAN CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ADVANCED RECURRENT OVARIAN CANCER MARKET DYNAMICS
TABLE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ENDOMETRIOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY MUCINOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SEROUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GERM CELL TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TAMOXIFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 79. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 80. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 82. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 83. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 84. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 85. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 86. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 87. CANADA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 96. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 97. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 135. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 136. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 137. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 141. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 142. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 143. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 144. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 147. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 148. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 152. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 153. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 154. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 155. INDIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 168. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 169. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 170. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 173. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 174. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 175. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 176. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 177. JAPAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 198. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 208. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 209. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 218. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 219. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 220. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 234. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 235. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 236. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 238. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 239. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 240. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 241. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 242. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 243. THAILAND ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 245. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 246. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 247. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 251. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 252. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 253. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 267. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 268. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 269. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 270. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 271. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 272. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 273. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 274. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 275. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI-ANGIOGENIC AGENTS, 2018-2030 (USD MILLION)
TABLE 277. DENMARK ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 279. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 280. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-EPITHELIAL OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 281. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 283. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 284. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM-BASED CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 285. EGYPT ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY

Companies Mentioned

The leading players in the Advanced Recurrent Ovarian Cancer Market, which are profiled in this report, include:
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Clovis Oncology
  • Eli Lilly and Company
  • Exelixis
  • Genentech
  • GSK
  • ImmunoGen
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Seagen
  • Tesaro
  • Vertex Pharmaceuticals

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.64 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Advanced Recurrent Ovarian Cancer - Pipeline Insight, 2024 - Product Image

Advanced Recurrent Ovarian Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Ovarian Cancer Pipeline Analysis Report - Product Image

Ovarian Cancer Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Ovarian Cancer Market Report by Type, Treatment Type, End User, and Region 2024-2032 - Product Image

Ovarian Cancer Market Report by Type, Treatment Type, End User, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From
Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region - Product Image

Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region

  • Report
  • 200 Pages
  • Global
From
Ovarian Cancer Opportunity Assessment and Forecast - Product Image

Ovarian Cancer Opportunity Assessment and Forecast

  • Report
  • 79 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.